Skip to main content
Premium Trial:

Request an Annual Quote

Atlas Venture Raises $950 Million For Venture Capital Fund

NEW YORK, April 26 - Atlas Venture has raised $950 million from institutional investors to start a new capital fund that will invest in early-stage communications, information technology, and life science companies, the venture capital firm said Thursday.

The new fund, called Atlas Venture VI, will invest in both US and European early-stage companies, and will likely divide funding equally between the three business sectors, said a spokeswoman for Atlas Venture.

In the past, Atlas has invested in life science companies such as DeCode Genetics, Ciphergen Biosystems, Structural Genomix, and Signature Bioscience.

Atlas is also currently raising money to establish a parallel fund for entrepreneurs and other individual investors, to invest alongside the main fund. Together the two funds will have a total value just shy of $1 billion, the spokeswoman said.

The fund is the sixth for 21-year old Atlas Venture, which has over $2.5 billion in committed capital in 300 companies.  
The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.